BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, August 7, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» BMF-219 demonstrates efficacy in DLBCL and MM preclinical models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
2022 International Myeloma Workshop
BMF-219 demonstrates efficacy in DLBCL and MM preclinical models
Aug. 30, 2022
No Comments
Researchers from Biomea Fusion Inc. presented preclinical data for the novel covalent menin inhibitor,
BMF-219
, after being evaluated in models of diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
BioWorld Science
Conferences
Cancer